Acebilustat

October 29, 2018October 29, 2018

#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows

cystic fibrosis, News

Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency and delays the onset of pulmonary exacerbations in CF patients, results from ... Read more

August 6, 2018August 6, 2018

Acebilustat Seen to Prevent Pulmonary Exacerbations in CF Patients in Phase 2b Trial

cystic fibrosis, News

Topline data from a Phase 2b trial showed that the investigative therapy acebilustat taken once daily can reduce the number and frequency of pulmonary exacerbations in patients with cystic fibrosis (CF). ... Read more

May 22, 2018May 22, 2018

#ECFS2018 — Celtaxsys Completes Phase 2b Trial Assessing Acebilustat in Cystic Fibrosis Patients

cystic fibrosis, News

Celtaxsys has completed its Phase 2b trial assessing the safety and effectiveness of acebilustat (formerly CTX-4430) for cystic fibrosis (CF), with the company announcing the last visit of the last ... Read more

February 5, 2018February 5, 2018

Celtaxsys Receives New Patent for Its CF Inflammation Therapy Acebilustat

cystic fibrosis, News

Celtaxsys has obtained four U.S. patents, including a new one for acebilustat, its lead candidate for treating the lung inflammation found in cystic fibrosis. The other three patents cover potential therapies ... Read more

January 10, 2018January 10, 2018

Celtaxsys Obtains Financing for Phase 3 Trial of Its Cystic Fibrosis Therapy Acebilustat

cystic fibrosis, News

Celtaxsys has obtained financing for a Phase 3 clinical trial of acebilustat as a treatment for cystic fibrosis. Acebilustat inhibits an enzyme that takes part in the production of a substance ... Read more

May 19, 2017May 19, 2017

Phase 2 Study of Oral Acebilustat in Treating Lung Inflammation Fully Enrolled in US, Europe

cystic fibrosis, News

Celtaxsys announced it has completed enrollment of its Phase 2b clinical trial evaluating the company’s lead anti-inflammatory candidate, oral acebilustat, in adult patients with cystic fibrosis (CF). Acebilustat (formerly known as ... Read more

November 11, 2016November 11, 2016

Encouraging Phase 1 Trial Results of Anti-inflammatory Oral Treatment for CF Published

News

Celtaxsys recently announced that a second study describing the results of Phase 1 clinical trials evaluating acebilustat, an oral treatment for cystic fibrosis (CF), has been published. A Phase 2 study is underway ... Read more

October 9, 2015October 19, 2015

Celtaxsys Begins US Clinical Trial to Test Acebilustat Drug Efficacy in CF Patients

cystic fibrosis, News

Celtaxsys, a pharmaceutical company focused on novel therapeutics to treat inflammatory diseases, announced that it is beginning enrollment of patients for a phase 2 clinical trial to test the efficacy ... Read more

Pin It on Pinterest